BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

IDrugs : the investigational drugs journal (2004-01-20)

R Todd Reilly

RÉSUMÉ

BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.

MATÉRIAUX

Numéro du produit

Marque

Description du produit

Y0000317

Mesna impurity D, European Pharmacopoeia (EP) Reference Standard